Follow-up probiotic ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 193 | Prader-Willi syndrome | 1 |
193. Prader-Willi syndrome
Clinical trials : 111 / Drugs : 120 - (DrugBank : 30) / Drug target genes : 51 - Drug target pathways : 103
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04685057 (ClinicalTrials.gov) | January 11, 2021 | 2/12/2020 | Probiotic Treatment for Prader-Willi Syndrome | Probiotics as a Long-term Treatment Strategy for Prader-Willi Syndrome | Prader-Willi Syndrome | Dietary Supplement: Placebo;Dietary Supplement: Probiotic;Dietary Supplement: Follow-up probiotic | Fundació Sant Joan de Déu | NULL | Enrolling by invitation | 6 Years | 30 Years | All | 50 | Phase 1/Phase 2 | Spain |